FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012035286> ?p ?o ?g. }

• W2012035286 endingPage "160" @default.
• W2012035286 startingPage "153" @default.
• W2012035286 abstract "The Veterans Affairs HDL Intervention Trial (VA-HIT) showed that gemfibrozil, which activates peroxisome proliferator-activator receptor alpha (PPARalpha), significantly reduced the risk of cardiovascular (CV) events in men with low HDL cholesterol (< 40 mg/dl) and established coronary heart disease. Treatment was particularly beneficial in those with insulin resistance (IR) or diabetes mellitus (DM). We hypothesized that the association between a functional polymorphism at the PPARA locus (L162V) and the risk of a CV event, as well as response to fibrate therapy, might be greatest in those with either IR or DM (DM/IR) in VA-HIT.A total of 827 men (placebo, n = 413; gemfibrozil, n = 414) from the VA-HIT were genotyped. This population included a high proportion of subjects with DM/IR. In VA-HIT, the PPARA V162 allele was associated with reduced levels of HDL cholesterol and the presence of DM/IR at baseline. It was also associated with reduced risk of CV events in those with DM/IR but not in those with neither (DM/IR *PPARA genotype, P = 0.005). Among subjects with DM/IR, treatment with gemfibrozil reduced CV events in non-carriers from 29.9 to 17.8% and carriers of the V162 allele from 14.7 to 4.8%. In contrast, carriers of the V162 allele with no DM/IR who were treated with gemfibrozil experienced significantly more CV events than did those who received placebo (20.6% versus 13.6%; P = 0.01).The effect of the L162V polymorphism at the PPARA locus on CV risk depends on the presence of DM/IR. Among subjects treated with gemfibrozil, the V162 allele was associated not only with reduced CV risk in subjects with DM/IR, but also with significantly increased CV risk in the absence of these traits, identifying this genetic variant as a potential marker for predicting which subjects may have a favorable response to fibrate therapy." @default.
• W2012035286 created "2016-06-24" @default.
• W2012035286 creator A5004599362 @default.
• W2012035286 creator A5012408085 @default.
• W2012035286 creator A5049068947 @default.
• W2012035286 creator A5054485925 @default.
• W2012035286 creator A5064285461 @default.
• W2012035286 creator A5073235477 @default.
• W2012035286 creator A5076060147 @default.
• W2012035286 creator A5083181297 @default.
• W2012035286 date "2006-07-01" @default.
• W2012035286 modified "2023-10-11" @default.
• W2012035286 title "The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trial (VA-HIT)" @default.
• W2012035286 cites W10628619 @default.
• W2012035286 cites W1567127662 @default.
• W2012035286 cites W1975107195 @default.
• W2012035286 cites W1994691874 @default.
• W2012035286 cites W1998624053 @default.
• W2012035286 cites W2034722415 @default.
• W2012035286 cites W2039592725 @default.
• W2012035286 cites W2051583212 @default.
• W2012035286 cites W2056539295 @default.
• W2012035286 cites W2060886627 @default.
• W2012035286 cites W2065633795 @default.
• W2012035286 cites W2082375016 @default.
• W2012035286 cites W2086174975 @default.
• W2012035286 cites W2089016920 @default.
• W2012035286 cites W2096350775 @default.
• W2012035286 cites W2102011776 @default.
• W2012035286 cites W2102906564 @default.
• W2012035286 cites W2107159320 @default.
• W2012035286 cites W2108886453 @default.
• W2012035286 cites W2111251212 @default.
• W2012035286 cites W2117092539 @default.
• W2012035286 cites W2123404136 @default.
• W2012035286 cites W2125161216 @default.
• W2012035286 cites W2128722360 @default.
• W2012035286 cites W2141694491 @default.
• W2012035286 cites W2154877324 @default.
• W2012035286 cites W2160234571 @default.
• W2012035286 cites W2168295930 @default.
• W2012035286 cites W2328529137 @default.
• W2012035286 cites W2330456176 @default.
• W2012035286 cites W2400712338 @default.
• W2012035286 cites W2738204019 @default.
• W2012035286 cites W4248880909 @default.
• W2012035286 doi "https://doi.org/10.1016/j.atherosclerosis.2005.08.034" @default.
• W2012035286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16221474" @default.
• W2012035286 hasPublicationYear "2006" @default.
• W2012035286 type Work @default.
• W2012035286 sameAs 2012035286 @default.
• W2012035286 citedByCount "40" @default.
• W2012035286 countsByYear W20120352862012 @default.
• W2012035286 countsByYear W20120352862013 @default.
• W2012035286 countsByYear W20120352862014 @default.
• W2012035286 countsByYear W20120352862015 @default.
• W2012035286 countsByYear W20120352862020 @default.
• W2012035286 countsByYear W20120352862023 @default.
• W2012035286 crossrefType "journal-article" @default.
• W2012035286 hasAuthorship W2012035286A5004599362 @default.
• W2012035286 hasAuthorship W2012035286A5012408085 @default.
• W2012035286 hasAuthorship W2012035286A5049068947 @default.
• W2012035286 hasAuthorship W2012035286A5054485925 @default.
• W2012035286 hasAuthorship W2012035286A5064285461 @default.
• W2012035286 hasAuthorship W2012035286A5073235477 @default.
• W2012035286 hasAuthorship W2012035286A5076060147 @default.
• W2012035286 hasAuthorship W2012035286A5083181297 @default.
• W2012035286 hasConcept C126322002 @default.
• W2012035286 hasConcept C134018914 @default.
• W2012035286 hasConcept C142724271 @default.
• W2012035286 hasConcept C204787440 @default.
• W2012035286 hasConcept C27081682 @default.
• W2012035286 hasConcept C2776933373 @default.
• W2012035286 hasConcept C2777391703 @default.
• W2012035286 hasConcept C2778163477 @default.
• W2012035286 hasConcept C2778670441 @default.
• W2012035286 hasConcept C2908647359 @default.
• W2012035286 hasConcept C555293320 @default.
• W2012035286 hasConcept C71924100 @default.
• W2012035286 hasConcept C99454951 @default.
• W2012035286 hasConceptScore W2012035286C126322002 @default.
• W2012035286 hasConceptScore W2012035286C134018914 @default.
• W2012035286 hasConceptScore W2012035286C142724271 @default.
• W2012035286 hasConceptScore W2012035286C204787440 @default.
• W2012035286 hasConceptScore W2012035286C27081682 @default.
• W2012035286 hasConceptScore W2012035286C2776933373 @default.
• W2012035286 hasConceptScore W2012035286C2777391703 @default.
• W2012035286 hasConceptScore W2012035286C2778163477 @default.
• W2012035286 hasConceptScore W2012035286C2778670441 @default.
• W2012035286 hasConceptScore W2012035286C2908647359 @default.
• W2012035286 hasConceptScore W2012035286C555293320 @default.
• W2012035286 hasConceptScore W2012035286C71924100 @default.
• W2012035286 hasConceptScore W2012035286C99454951 @default.
• W2012035286 hasIssue "1" @default.
• W2012035286 hasLocation W20120352861 @default.
• W2012035286 hasLocation W20120352862 @default.
• W2012035286 hasOpenAccess W2012035286 @default.
• W2012035286 hasPrimaryLocation W20120352861 @default.

• next